Are you wondering if it is true that the Hepatitis C market is the new number one focus of the pharmaceutical giants? Yes, the introduction of the Protease Inhibitors and the success of the treatment has blow the market wide open. It is truly a time of money to be made, according to Market Watch and other major financial sites. The infection rates are high all over the globe with little or no treatment available. HCV treatment is expensive, but it is becoming a worldwide necessity.
 |
| Shockingly High: The Global Percentages of Hepatitis C Infection Rates |
This article from the Wall Street Journal about an eleven billion dollar gambit (yes that is $11 billion dollars) by Gilead is a perfect example of the truth of the above statement.
Here is the beginning of the article by Ron Winslow and Peter Loftus.
Wall Street Journal (11-22-2011) Gilead Sciences Inc.'s agreement to pay nearly $11 billion to acquire tiny Pharmasset Inc. is a dramatic illustration of the market potential—and public-health challenges—involved in the battle against the hepatitis C virus.
Pharmasset, a Princeton, N.J., company with just over 80 employees and no commercial products, is developing a compound that Gilead and analysts say is on track to be part of the first all-oral regimen for treating hepatitis C. Experts say that gives it a distinct advantage over current treatments in the potentially huge U.S. and global markets for such drugs.
No comments:
Post a Comment